Particle.news
Download on the App Store

MoonLake Investor Lawsuits Press Toward Lead-Plaintiff Cutoff as December 15 Deadline Nears

Fresh filings spotlight allegations over sonelokimab marketing following the September share collapse.

Overview

  • Berger Montague announced a class action for purchasers of MoonLake shares between March 10, 2024 and September 29, 2025.
  • Bernstein Liebhard reported a shareholder suit and invited investors to discuss their options, with motions for lead plaintiff due December 15, 2025.
  • The Gross Law Firm urged investors to seek lead-plaintiff roles and outlined claims that SLK and BIMZELX share IL‑17A and IL‑17F targets with no proven Nanobody-based superiority.
  • Complaints point to MoonLake’s September 28, 2025 Phase 3 disclosure as showing SLK missed efficacy benchmarks, followed by a nearly 90% single-session stock drop.
  • Investors may participate in any potential recovery without serving as lead plaintiff, and representation is offered on a contingency basis.